Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications
Erin Armideo, RN, CRNP, CPON, Colleen Callahan, RN, CRNP, and Lara Madonia, RN, CRNP
The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Erin Armideo, RN, CRNP, CPON, The Children’s Hospital of Philadelphia, 34th and Civic Center Boulevard, Philadelphia, PA 19104. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2017;8:44–55 |
© 2017 Harborside Press®
Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials. Immunotherapy has become the standard of care for patients with high-risk disease, and many institutions across the country are providing this therapy. The care of these patients is complex and often associated with many side effects. The purpose of this article is to review the most common side effects seen in clinical practice and examine their management. Furthermore, this article will discuss the need for a consistent and educated multidisciplinary front-line team to care for these patients, with advanced practitioners playing a lead role to provide the care and attention needed for this patient population.
For access to the full length article, please sign in